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Objectives: We previously demonstrated that calcineurin inhibitors given intrave-
nously ameliorate experimental lung ischemia-reperfusion injury. This study eval-
uates whether these effects can be achieved when these agents are delivered
endotracheally.
Methods: Left lungs of Long Evans rats were rendered ischemic for 90 minutes and
reperfused for up to 4 hours. Treated animals received tacrolimus endotracheally at
doses of 0.2, 0.1, or 0.025 mg/kg 60 minutes before ischemia. Injury was quantitated
in terms of vascular permeability. Additional animals treated at a dose of 0.1 mg/kg
were assessed for lung tissue myeloperoxidase content and bronchoalveolar lavage
leukocyte content. Bronchoalveolar lavage fluid was assessed for cytokine and
chemokine content by enzyme-linked immunosorbent assay. Tissue samples were
processed for nuclear factor-B activation, and blood levels of tacrolimus were
measured in treated animals.
Results: Left lung vascular permeability was reduced in treated animals in a dose-
dependent fashion compared with controls. The protective effects correlated with a 47%
(0.50% 0.06% vs 0.27% 0.08%, respectively) reduction in tissue myeloperoxidase
content (P  .004) and marked reductions in bronchoalveolar lavage leukocyte accu-
mulation. This protection was also associated with decreased nuclear factor-B activa-
tion and diminished expression of proinflammatory mediators. Blood tacrolimus levels
in treated animals at 4 hours of reperfusion were undetectable.
Conclusions: Tacrolimus administered endotracheally is protective against lung
ischemia-reperfusion injury in our model. This protection is associated with a
decrease in nuclear factor-B activation. This route of tacrolimus administration
broadens its potential clinical use and decreases concerns about systemic and renal
toxicity. It may be a useful therapy in lung donors to protect against lung ischemia-
reperfusion injury.
Lung ischemia-reperfusion injury (LIRI) is a major complication afterlung transplantation and is associated with an increase in vascularpermeability that manifests itself clinically as pulmonary edema.1Despite improvements in organ preservation techniques,2 LIRI per-sists and compromises both early and late graft function. In animalmodels, this injury has been shown to be biphasic.3 The late phase is
dependent on neutrophil recruitment, whereas the early stage is independent of it,
occurring within 15 minutes of reperfusion. The early phase also seems to involve
signaling events that lead to the full development of tissue injury after several hours
of reperfusion.
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Tacrolimus (TAC) is an immunosuppressive agent that
has been used in solid-organ transplantation for almost 2
decades. The immunomodulatory effects of TAC involve
the inhibition of the tyrosine phosphatase calcineurin. TAC
is a macrolide antibiotic that binds to a cytoplasmic protein,
FK binding protein, and inhibits calcineurin. TAC is 100
times more potent than the other commonly used cal-
cineurin inhibitor, cyclosporine A (CsA). Inhibition of cal-
cineurin in turn reduces the expression of a number of
transcription factors, including nuclear factor of activated T
cell (NF-AT), Oct-1, AT-1, and NF-B. All of these tran-
scription factors can bind to different sequences on the
interleukin-2 promoter. The most critical of these in immu-
nomodulation is NF-AT. Decreased transcription factor ac-
tivity results in a diminished production of interleukin-2
messenger RNA and protein, which subsequently blunts the
T-cell response that mediates cellular rejection.
Although effects on NF-AT are known to be central to
the immunomodulatory effects of TAC, its effects on
NF-B are of great interest in inflammatory conditions.
NF-B is a transcription factor that has a wide range of
activities including modulation of cell growth and death,
regulation of immune function, and apparent effects on
acute reperfusion injury.4 Calcineurin inhibitors have been
shown to be protective in reperfusion injury of the brain,
kidney, liver, and heart.5-8 We previously demonstrated that
intravenous calcineurin inhibition with both CsA and TAC
is effective in ameliorating experimental LIRI.9 We also
showed that CsA attenuates proinflammatory chemokine
secretion in alveolar macrophages in an in vitro hypoxia and
reoxygenation model.10 Previous in vitro studies delineated
the mechanism by which CsA and TAC may inhibit NF-B
activation.11,12 It has been suggested that calcineurin inhi-
bition blocks the degradation of IB, the cytoplasmic pro-
tein that binds NF-B in its inactive form, therefore decreas-
ing the levels of active NF-B. In addition, calcineurin
inhibition decreases processing of proform precursors of
NF-B to its functional heterodimeric form. Therefore, cal-
cineurin inhibitors lead to diminished concentration of ac-
tive NF-B in the nucleus, which leads to decreased pro-
duction of mRNA for proinflammatory cytokines,
neutrophil adhesion molecules, procoagulant proteins, and
vasoconstrictive substances. It seems that many of the anti-
inflammatory properties of calcineurin inhibitors are mod-
ulated through its effects on NF-B and are separate from
its immunomodulation, which occurs through NF-AT inhi-
bition. Increased sensitivities among macrophages and neu-
trophils, as opposed to T lymphocytes, help explain the
differential anti-inflammatory and immunomodulatory ef-
fects of the same drugs.
Early studies of calcineurin inhibition during organ isch-
emia-reperfusion (I/R) injury involved animals that were
treated with either CsA or TAC during the week preceding
the experiment.13-15 This makes clinical translation difficult.
Although protection was seen in these models, such a strat-
egy would be very difficult to implement in human trans-
plant recipients. More recent studies in cardiac and cerebral
models have shown protection against I/R injury when
administered at or close to the time of onset of ischemia or
even with treatment early after its onset.16,17
We previously demonstrated that the alveolar macro-
phage is the central orchestrating cell in LIRI.18,19 Endotra-
cheal agents targeting these cells have been protective in
other models of acute lung injury.20 Therefore, we hypoth-
esized that delivering TAC endotracheally would treat these
cells directly and provide protection similar to that seen
with intravenous administration. We further hypothesized
that systemic levels of TAC would be low with this route of
delivery and that this could be useful in reducing potential
negative side effects of intravenous drug administration.
Finally, knowing that previous studies have suggested that
the protective effects of TAC may be mediated by modu-
lation of NF-B, we hypothesized that any protection would
be associated with reduced activation of NF-B and expres-
sion of proinflammatory mediators.
Methods
Reagents
All reagents were purchased from Sigma Chemical (St. Louis, Mo)
unless otherwise specified. The commercial preparation of the
calcineurin inhibitor TAC (Fujisawa, Deerfield, Ill) was obtained
from the inpatient pharmacy at the University of Washington in
Seattle.
Animal Model
Pathogen-free, adult male Long-Evans rats (Simonsen Labs, Gil-
roy, Calif), weighing 250 to 275 g, were used for all experiments.
All animals received humane care in compliance with the “Guide
for the Care and Use of Laboratory Animals,” published by the
National Society for Medical Research and the National Institute
of Health. An in situ warm I/R model was used as described
previously.9 Treated animals received TAC through their endotra-
cheal tube at doses of 0.2, 0.1, or 0.025 mg/kg 1 hour before any
experimental procedure. Further animals received an equivalent
volume of vehicle. In brief, anesthesia was induced with pento-
barbital, and animals were ventilated by tracheostomy (Harvard
Rodent Ventilator, Harvard Apparatus Inc, Holliston, Mass). All
animals received 0.2 mg of atropine intramuscularly and 50 units
of intravenous heparin. Anesthesia was maintained with inhaled
halothane. The left lung was mobilized atraumatically through an
anterolateral thoracotomy, and the left pulmonary artery, veins,
and main stem bronchus were occluded with a noncrushing mi-
crovascular clamp. At the end of the 90-minute ischemic period,
the clamp was removed and the lung was ventilated and reperfused
for periods of up to 4 hours. At the conclusion of the reperfusion
period, blood samples were obtained from the inferior vena cava,
the heart lung block was rapidly excised, and the pulmonary
circulation was flushed with 20 mL of normal saline through the
main pulmonary artery.
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Lung Permeability Index
To quantitate lung injury, a permeability index was determined as
described previously.9,18 I125-radiolabeled bovine serum albumin
(NEN Life Sciences, Boston, Mass), titrated to an activity of
800,000 counts · min · dose, was intravenously injected in a final
volume of 1 mL of 1% bovine serum albumin phosphate-buffered
saline solution 5 minutes before removal of the hilar clamp. At the
end of the experiment, the radioactivity counts were quantitated in
the left lung and in 1 mL of inferior vena cava blood using a
scintillation counter. The permeability index was then calculated
as follows:
Permeability index
Left lung (counts/min)
1.0 mL blood (counts/min)
This ratio corrected for any variation in systemic blood levels of
radioactivity and provided a reproducible measure of lung micro-
vascular permeability.
Myeloperoxidase Assay
Tissue myeloperoxidase (MPO) content was used to quantitate
neutrophil accumulation in the left lung as described previously.9
Lung samples were homogenized in a phosphate buffer containing
0.5% hexadecyltrimethylammonium bromide. Samples were then
assayed for the ability to decompose H2O2 in the presence of
O-dianisidine dihydrochloride by the change in absorption at 460
nm during 1 minute.
Bronchoalveolar Lavage
Additional animals underwent bronchoalveolar lavage (BAL) at
the time of death. Through the tracheostomy, lungs were lavaged
individually by clamping the contralateral hilum and instilling 3.0
mL of saline that was flushed and aspirated 3 times. This fluid was
centrifuged (1500g  8 minutes at 4°C) to pellet the cells, and the
supernatant was snap-frozen for subsequent cytokine analysis after
the addition of a protease cocktail inhibitor (leupeptin 1 g/mL,
aprotinin 1 g/mL, trypsin inhibitor 5 g/mL, and pepstatin A 1
g/mL). The red blood cells were lysed, and the pellet was
resuspended in normal saline. Total nucleated cells were counted
using a hemacytometer (Hausser Scientific, Reading, Pa).
Enzyme-Linked Immunosorbent Assay of BAL for
Cytokine Content
Sandwich enzyme-linked immunosorbent assays for macrophage
inflammatory protein (MIP)-1, cytokine-induced neutrophil che-
moattractant (CINC), and tumor necrosis factor (TNF)- were
developed in our laboratory.18 Fifty microliters of a 1-g/mL
protein-A purified specific antichemokine antibody (Peprotech,
Rocky Hills, NJ) in a carbonate-coating buffer solution (pH 9.6)
was added to a 96-well (Dynex, Chantilly, Va) immunoassay plate.
The plate was incubated overnight at 4°C and washed with phos-
phate-buffered saline with 0.05% Tween. One percent bovine
serum albumin in saline was used to block nonspecific binding
(30-minute incubation at 37°C). Samples and standards were di-
luted in saline, and 50 L was added to each well (1-hour incu-
bation at 37°C). A secondary, affinity-purified, biotinylated anti-
body (Peprotech, Rocky Hills, NJ) specific to the epitope being
studied (0.5-2 g/mL) was added to each well (1-hour incubation
at 37°C). After a 30-minute incubation with a streptavidin-horse-
radish-peroxidase conjugate (Pierce, Rockford, Ill), the assay was
developed by adding O-phenylenediamine dihydrochloride sub-
strate. The linear sensitivity range of the assays was determined,
and the assays showed no cross-reactivity with each other. Sam-
ples and standards were run in triplicate, and well-to-well variation
did not exceed 5%.
Electrophoretic Mobility Shift Assay
Left lungs were snap-frozen at the end of the experimental proto-
cols. These frozen tissue samples were ground to a fine powder and
then suspended in 4.0 mL of buffer containing 0.06% Nonidet
P-40, 150 mmol/L NaCl, 10 mmol/L HEPES, 1 mmol/L EDTA,
and 0.5 mmol/L PMSF. The solution was then homogenized and
centrifuged for 15 seconds (12,000g). The pellet was discarded,
and the supernatant was cooled to 4°C. The supernatant was then
centrifuged again for 15 seconds (12,000g). The resultant pellet
was suspended in 40 L of buffer containing 40 mmol/L NaCl, 20
mmol/L HEPES, 0.2 mmol/L EDTA, 1.2 mmol/L MgCl2, 0.5
mmol/L PMSF, 0.5 mmol/L DDT, 25% glycerol, 5 g/mL apro-
tinin, and 5 g/mL leupeptin for 20 minutes at 4°C. This solution
was then centrifuged for 5 minutes, the pellet was discarded, and
the supernatant containing the nuclear protein was stored at
70°C. Quantification of nuclear protein was performed using the
bichinoic acid assay.
Ten micrograms of nuclear protein were incubated in a binding
reaction with either double-stranded 32P end-labeled oligonucle-
otide containing the NF-B or activator protein-1 consensus bind-
ing sequence (Promega, Madison, Wis). The binding reaction was
performed at room temperature for 60 minutes, and the proteins
were resolved on a 6% nondenaturing polyacrylamide gel at 100V
for 1 to 2 hours. The gels were dried and autoradiographed.
Densitometry was performed with Image J software (version 1.2;
Cybernetics Corp, Silver Spring, Md) to assess relative signal
intensity.
Blood TAC Levels
Blood levels of TAC were measured in animals treated at a dose of
0.1 mg/kg 1 hour after administration of the drug and at 4 hours of
reperfusion (6.5 hours postadministration). All measurements were
performed by the University of Washington clinical laboratories.
Statistical Analysis
All data are presented as mean  SEM. Data sets were analyzed
using Microsoft Excel 2000 and SPSS (version 10, Microsoft Inc,
Redmond, Wash). Comparisons between control groups or be-
tween positive controls and treated animals were performed using
the Student t test. Analyses between more than 2 groups were
performed with analysis of variance with control for multiple
comparisons.
Results
Effect of Endotracheal TAC Pretreatment on Lung
Vascular Permeability
The left lung permeability index increased from 0.09 
0.005 in unmanipulated animals to 0.80 0.04 among an-
imals receiving vehicle and undergoing 90 minutes of is-
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chemia followed by 4 hours of reperfusion (P  .001).
Endotracheal TAC pretreatment at doses of 0.2, 0.1, and
0.025 mg/kg reduced lung vascular permeability by 70%,
67%, and 30%, respectively, after 4 hours of reperfusion
(Figure 1) (P  .005 for all 3 groups, N  4). Because no
statistically significant difference was seen between protec-
tion with doses of 0.2 and 0.1 mg/kg of TAC, the lower dose
of 0.1 mg/kg was chosen for all further experiments.
Effect of Endotracheal TAC Pretreatment on Lung
MPO Content
Lung tissue MPO content increased from 0.012  0.003
among unmanipulated animals to 0.51  0.3 in the vehicle-
treated group undergoing 90 minutes of ischemia followed
by 4 hours of reperfusion (P  .001). There was a 48%
reduction in tissue MPO content among TAC-treated ani-
mals undergoing the same periods of I/R at a dose of 0.1
mg/kg (0.27  0.04, P  .004, N  4) (Figure 2).
Effect of Endotracheal TAC Pretreatment on BAL
Cell Counts
BAL cell count increased 20-fold among vehicle-treated
animals undergoing 90 minutes of ischemia followed by 4
hours of reperfusion compared with unmanipulated animals
(0.84  0.13-16.5  0.81, P  .001). There was a 77%
reduction in BAL cell count associated with TAC (0.1
mg/kg) treatment in animals undergoing the same periods of
I/R (4.38  0.4, P  .001, N  4) (Figure 3).
Effect on Cytokine Content in BAL Associated with
Endotracheal TAC Pretreatment
Three groups were studied: unmanipulated animals, vehi-
cle-treated animals that underwent 90 minutes of ischemia
followed by 4 hours of reperfusion, and endotracheal TAC-
pretreated animals (0.1 mg/kg) subjected to the same LIRI
protocol. CINC expression increased from 0.052 0.003 to
2.9  0.2 ng/mL between unmanipulated and vehicle-
treated animals. A 65% decrease was demonstrated in the
TAC-treated group to 1.04  0.1 ng/mL (P  .002) (Figure
4, A). MIP-1 increased from 0.03  0.002 ng/mL to 0.34
 0.019 ng/mL between unmanipulated and vehicle-treated
animals, respectively. This increase was almost completely
blocked with TAC treatment, giving a reduction of 93% to
0.055  0.004 ng/mL (P  .001) (Figure 4, B). TNF-
content of lavage fluid was increased in vehicle-treated
animals undergoing 90 minutes of ischemia and 4 hours of
reperfusion when compared with unmanipulated animals
(27.5 6.8 pg/mL vs 67.5 4.4 pg/mL). This increase was
decreased by 69% with TAC treatment to 39.6 4.2 pg/mL
(P  .03) (Figure 4, C).
Effect on NF-B Activation by Endotracheal TAC
Pretreatment
To explore the potential mechanisms mediating the protec-
tion seen with TAC in LIRI, the effects on expression of the
proinflammatory transcription factor NF-B were assessed.
The band that is representative for NF-B was specified
using cold competition with nonlabeled oligonucleotide.
The time point of 15 minutes of reperfusion was used
because this is the early peak in injury, and we previously
demonstrated high levels of NF-B activation at this time in
our model when compared with unmanipulated animals
(data not shown). A representative electrophoretic mobility
shift assay (EMSA) is shown in Figure 5, A. As can be seen,
there is marked NF-B nuclear translocation in vehicle-
treated animals undergoing 90 minutes of ischemia fol-
lowed by 15 minutes of reperfusion, and this is decreased in
endotracheal TAC-treated lungs (N  3). Densitometric
analysis is depicted below the autoradiograph and reveals a
statistically significant reduction in NF-B nuclear translo-
cation with TAC treatment (P  .003) (Figure 5, B).
Blood TAC Levels
Blood TAC levels in animals receiving the 0.1 mg/kg dose
averaged 5.0  1.0 ng/mL 1 hour after administration. At 4
hours of reperfusion, blood TAC levels were below detect-
able limits in all animals studied at this dose.
Discussion
Calcineurin inhibitors such as TAC and CsA have been
shown to provide marked protection against I/R injury of
several organs, including the brain, heart, kidney, and liv-
Figure 1. There is a marked increase in permeability index be-
tween unmanipulated animals (normal) and vehicle-treated ani-
mals undergoing ischemia of 90 minutes followed by reperfusion
of 4 hours (IR4). TAC-treated animals showed protection against
increased vascular permeability at all 3 doses studied (P < .005
for all 3 groups). There was no significant difference in perme-
ability index between the 0.2 and 0.1 mg/kg doses. TAC, Tacroli-
mus; I/R, ischemia-reperfusion.
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er.5-8 There are several mechanisms that have been sug-
gested for this protection, which are in 3 broad categories:
effects on mitochondrial stabilization, effects on microcir-
culation, and effects on transcriptional regulation.21 Most of
the work studying the effects on mitochondrial stabilization
has been performed in tissues rich in mitochondria, such as
the heart and liver. In I/R injury in such tissues, CsA and
TAC have been shown to abrogate calcium influx and
decrease mitochondrial transition pore opening, which leads
to decreased tissue injury.22,23 However, these mitochon-
drial effects seem to play a lesser role in lung tissue.
Abnormalities in tissue microcirculation are known to be
important in I/R injury. It has been reported that protective
effects of CsA and TAC in hepatic I/R are associated with
maintenance or rapid restoration of normal parenchymal
blood flow.13,22 Endothelin-1 expression and effects on ni-
Figure 2. Left lung tissue MPO content increased dramatically between unmanipulated animals (normal) and
vehicle-treated animals undergoing 90 minutes of ischemia followed by 4 hours of reperfusion (IR4). MPO content
was significantly decreased with TAC treatment (0.1 mg/kg) (P < .001).
Figure 3. BAL cell count increased 20-fold between unmanipulated animals (normal) and vehicle-treated animals
undergoing 90 minutes of ischemia followed by 4 hours of reperfusion (IR4). Cell counts were decreased by 77%
in the TAC-treated group (0.1 mg/kg) (P < .001).
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tric oxide production have been shown to mediate variations
in vasomotor tone. In many organs, postischemic vasocon-
striction is believed to decrease tissue edema through de-
creased starling forces. However, such vasoconstriction in
the lung may adversely affect lung function and proper gas
exchange.
In LIRI, the dominant mechanism of protection by cal-
cineurin inhibition likely relates to effects on transcriptional
up-regulation of proinflammatory mediators. We previously
demonstrated that intravenous treatment with both CsA and
TAC was protective in a rat model of LIRI.9 Furthermore,
this protection was shown to be associated with modulation
of the transcription factor NF-B and a decrease in proin-
flammatory mediator expression. Recent work in renal I/R
injury has demonstrated changes in mitogen-activated pro-
tein kinase activity with both CsA and TAC treatment.6
These effects on upstream signaling kinases may explain
further the protective effects of calcineurin inhibition in I/R
injury.
The alveolar macrophage has been identified as a key
effector cell in lung reperfusion injury.24 We have previ-
ously shown that depletion of macrophages or inhibition of
macrophage function are both protective in LIRI.18,19 It
seems that alveolar macrophages play a very important role
in the early stages of reperfusion injury and set up an
inflammatory cascade leading to the later full blown injury.
In previous in vitro studies, we showed that CsA attenuates
the expression of a number of proinflammatory mediators
Figure 4. A, There was a marked increase in BAL CINC content in vehicle-treated animals undergoing 90 minutes
of ischemia followed by 4 hours of reperfusion (IR4) compared with unmanipulated animals (normal). TAC
treatment (0.1 mg/kg) significantly decreased CINC levels in BAL fluid (P < .002). B, MIP-1 content of BAL fluid
was increased in vehicle-treated animals undergoing 90 minutes of ischemia followed by 4 hours of reperfusion
(IR4) compared with unmanipulated animals (normal). TAC treatment (0.1 mg/kg) decreased this by 93% (P < .001).
C, TNF- content in BAL increased in vehicle-treated animals undergoing 90 minutes of ischemia followed by 4
hours of reperfusion (IR4) compared with unmanipulated animals (normal). TAC treatment (0.1 mg/kg) decreased
this by 69% (P < .03).
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secreted by primary harvested alveolar macrophages in re-
sponse to hypoxia followed by reoxygenation.10 Therefore,
by delivering a drug into the intra-alveolar compartment
through the endotracheal route, these orchestrating cells
would be treated directly, limiting their early response
(which incites the inflammatory cascade leading to LIRI).
The endotracheal route would also likely allow protection to
be achieved with a lower systemic drug concentration be-
cause the drug is being delivered directly to the cells in-
volved in LIRI rather than systemically. This route would
therefore be more attractive in the clinical setting of organ
donors because the potential problems of renal or hepatic
toxicity would be minimal.
In this study, we showed that TAC is protective against
LIRI when delivered through the endotracheal route. Sig-
nificant protection against an increase in lung vascular per-
meability was achieved at all 3 doses used. Furthermore,
this protection was not significantly different between the
0.2 and 0.1 mg/kg doses. The degree of protection achieved
at both of these doses was greater than that previously
demonstrated with intravenous TAC administration at a
dose of 0.2 mg/kg.9 This protection was associated with a
decrease in both lung tissue and alveolar space neutrophil
sequestration as assessed by MPO content and BAL cell
counts. Endotracheal TAC pretreatment was associated with
a decrease in expression of the proinflammatory cytokines
CINC, TNF-, and MIP-1, as well as a decrease in nuclear
translocation of NF-B. This is in keeping with our and
other investigators’ previous work showing that calcineurin
inhibition modulates NF-B activity.8,9 The results of TAC
blood levels were very encouraging: At the dose used for
most experiments (0.1 mg/kg), TAC blood levels were
below detectable limits at 4 hours of reperfusion. Earlier on
at 1 hour after administration, the mean TAC blood level
was 5.0 ng/mL, which is still at the lower end of the normal
therapeutic range used for immunosuppression protocols
with TAC. Furthermore, in such protocols, the TAC blood
levels used to establish dosing are trough levels normally
measured 12 hours after the last dose. It is these trough
levels that are important in determining TAC toxicity. Our
1-hour postadministration time point would be unlikely to
represent a trough level, whereas our 4-hour reperfusion
time point would be nearer to a true trough level. Therefore,
because the blood levels at 4 hours of reperfusion (6.5 hours
after administration) are undetectable, it is unlikely that this
dose of TAC would lead to toxic effects.
Figure 5. A, Representative EMSA for NF-B nuclear translocation. Cold competition (cold lane); vehicle-treated
animals that underwent 90 minutes of ischemia followed by 15 minutes of reperfusion (IR15 lanes); TAC-treated
animals (0.1 mg/kg undergoing the same periods of I/R (TAC lanes). There is less activation of NF-B in the
TAC-treated animals than in the vehicle-treated animals. B, Relative densitometry from EMSAs for NF-B nuclear
translocation. There is a decrease in relative densitometric value with TAC treatment when compared with the
vehicle-treated groups (P < .003).
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Conclusion
We have demonstrated that endotracheal TAC administra-
tion is protective against LIRI in our experimental model.
Furthermore, this protection is associated with a decrease in
both NF-B activity and proinflammatory cytokine expres-
sion. This represents a potentially useful therapy in lung
transplantation; however, further work is needed to evaluate
its effects in a whole-lung transplant model. One of the
potential concerns is that inhibition of NF-B in trans-
planted lungs is likely to have effects on several processes
as well as LIRI. For example, there is the potential that
prolonged NF-B inhibition could lead to delayed healing.
We believe that if TAC is administered as a single dose into
the lungs before ischemia and during the early reperfusion
period, the likelihood of such complications is low. We are
planning to investigate this in future experiments using a
whole-lung transplant model.
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Discussion
Dr Robert J. Keenan (Pittsburgh, Pa). I enjoyed your presen-
tation. I have a couple of questions. Obviously I/R injury and
immunomodulation go hand-in-hand, and it may be important
specifically when looking at procurement of the donors to consider
both factors in solutions derived at trying to improve overall lung
function. I noted that your analysis of NF-B showed that the
decline after 15 minutes was not in fact significant. Is your choice
of using 15 minutes signifying the early phase when you expect
NF-B levels to be highest? Is that just not the right time? Maybe
the NF-B is in fact not the right transcription factor, and maybe
there is another one that is as important, if not more important, or
maybe we’re just not talking about the right effector cell.
Dr Woolley. Actually it is significant, but it isn’t quantified in
the article because we don’t normally quantify our EMSAs. So it
was just a qualitative decrease described with TAC treatment. If
you actually go back and perform densitometry on all of the
images and then derive statistics, it is a statistically significant
decrease.
With respect to whether we’re looking at the right time, all of
the previous studies that have been performed in this model have
shown that NF-B activation is maximal at 15 minutes of reper-
fusion. We believe that the 15-minute injury peak that occurs in
this biphasic model is actually an early signaling event, because if
you look at permeability indices or MPO concentrations, they peak
at 15 minutes and then they go back down almost to baseline by
approximately 1 to 2 hours, and then you go on to get your
maximal full-blown injury at 4 hours of reperfusion. So we believe
that this first event is actually a signaling event and that NF-B at
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this time is actually causing other cells, such as rat pulmonary
endothelial cells and type II pneumocytes, to release more proin-
flammatory mediators that then set up the later full-blown injury.
As for whether we’re looking at the right effector cell, and I
presume you mean alveolar macrophages, we have performed
several studies looking at alveolar macrophages. We have used
gadolinium to suppress macrophage function, and we have per-
formed macrophage depletion studies using clodronate liposomes.
We found that depleting alveolar macrophages markedly decreases
lung I/R injury. We have also repeated all of these studies in vitro
using cultures of alveolar macrophages, type II pneumocytes, and
rat pulmonary endothelial cells. We found that it is the alveolar
macrophage that responds most to calcineurin inhibitors. Type II
pneumocytes don’t seem to do very much at all, and there is some
response in rat pulmonary endothelial cells, but it’s certainly not as
great as the response you get in the macrophage. So I think we are
actually looking at the right cells. As I say, when we go back and
look at the densitometry, it is actually significant. But we don’t
normally quantify our EMSAs—we usually just make a qualitative
analysis of them.
Dr Keenan. As a segue to the last point, then, does your BAL
cell count analysis corroborate your statement that the alveolar
macrophages are the ones that are diminished? When you look at
the cell counts, you’re looking potentially at PMNs as well as
macrophages?
Dr Woolley. Yes. The cell counts are at 4 hours, so they are
representing the late injury, and what we’re saying is that the
alveolar macrophages mediate the early 15-minute time point, not
the 4-hour injury. The 4-hour injury is all the neutrophils that have
been sequestered, and at that point, yes, there is a whole milieu of
cells with multiple cell types. We’re only saying that the alveolar
macrophages mediate the early time point, not the late time point
as well, and that they set up the cascade that leads to the late injury.
Dr Keenan. The major question I have is related to the other
effects that you talked about earlier. You honed in on the nuclear
transcription factors, but those other issues, maybe not so much the
mitochondrial factors, but the microcirculation factors, would
seem to be important in the lung. If you gave this intravenously to
the donor preoperatively, you might be able to achieve both some
alveolar effects and microcirculatory effects.
Dr Woolley. Yes, and we have actually given intravenous
TAC, as I said initially, and you’re right, intravenous TAC has
been shown to be markedly protective in I/R in the liver and
kidney. Yes, you may derive extra benefit from giving it like that.
In this study we were trying to look at whether TAC could be
potentially delivered through a nebulized route into the lungs of
donors and minimize the systemic levels, because the other side of
the coin is that if you have very high systemic concentrations, you
may run into problems with nephrotoxicity or similar effects, and
you don’t want to jeopardize any of the other organs. However, I
do agree with you that if it was at a low enough dose, you may well
find that it is potentially beneficial and that it might protect the
other organs being harvested at the same time.
Dr Thomas M. Egan (Chapel Hill, NC). Could you be a little
more specific about exactly how you delivered the 200 g into the
airway? Was it nebulized or did you just squirt it in? How did you
get it in there?
Dr Woolley. It wasn’t nebulized. We initially wanted to give it
nebulized but had trouble finding a system that could do that. So
we experimented with a lot of different ways of administering it to
actually get it down into the lungs. Eventually what we came up
with was that if we advanced the endotracheal tube right down
onto the bifurcation and delivered it with the animal in a left lateral
decubitus position, gravity would take it down into the left lung as
well. We then injected 200 L with 300 L of air behind it to clear
the dead space in the tube, so it would actually go down into the
lungs. We did some radiolabeling studies and found that we were
getting a ratio of 2.5:1, left to right, so most of the drug was getting
into the left lung rather than the right, but we couldn’t selectively
intubate, so we couldn’t inject it into the left lung alone.
Dr Egan. Have you performed any studies to look at providing
this agent at reperfusion rather than 1 hour before? This could be
a practical approach to treating non–heart-beating donors in whom
you have an airway.
Dr Woolley. Only intravenously. We haven’t done that yet
with the endotracheal route. That’s something we may think about
doing. But so far we’ve only done it with the intravenous route,
and it does provide protection if given at ischemia intravenously
but not quite as great as when given as a pretreatment.
Dr Stephen D. Cassivi (Rochester, Minn). I am very interested
in your work on this subject and I congratulate you for it.
I have a suggestion regarding possible future studies. I suppose
the next step I would envision is to see whether this actually works
in a simulated transplant situation. I know you’re probably guided
in Seattle by the fact that you also are very interested in I/R from
the standpoint of the pulmonary artery hypertensive work that Dr
Mulligan does. However, for those of us in the lung transplant field
it would be interesting to see whether your findings carry over in
an actual organ transplant model.
Dr Woolley. Yes, we’re trying to work toward that. At the
moment we don’t have an orthotopic lung transplant model, but Dr
Mulligan is currently doing some work with an orthotopic model
in dogs, and if we can, we will try and use this with that model. At
the moment we don’t physically have the facilities to do that yet.
Dr Cassivi. You could start with the very simple rat single-lung
transplant model. It’s a relatively smaller model and fairly simple
to get under way.
Dr Woolley. We are planning to use an orthotopic model in
rats, but we do not have that up and running at the moment.
Dr Robert J. Korst (New York, NY). What do you think the
downside of inhibiting NF-B in the airway is going to be in the
donor? Have you thought about any potential downsides? NF-B
is such a ubiquitous transcription factor, and there is undoubtedly
some inflammation that’s needed for such things like wound
healing and so forth. Do you have any thoughts on that?
Dr Woolley. If you’re giving it to the donor, then it shouldn’t
have much of an effect, because if you’re giving it either 1 hour
before harvesting the organs or at the time that you cause ischemia,
you won’t have time to worry about wound healing or similar
problems in the donor. In the recipient, obviously that would be an
issue, but it’s going to be such a small dose when you’ve trans-
planted the lung into the recipient that it really shouldn’t have
much of an effect.
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